Sign in to fuzzto save your conversations, follow your research and come back anytime.
Syngene International
SectorHealthcare
Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.
In the news
Syngene tumbles 9% to 52-week low after Q1 loss of ₹9 cr
Biocon Shares Hit 52-Week High at ₹444.50 on ₹3,481 Cr Mylan Block Deal
Syngene International appoints Siddharth Mittal as MD & CEO
Five stocks recommended for May 4 trading session
3 stocks to trade: Venkatraman's picks for May 4
Syngene shares surge 17% despite 20% profit decline to ₹380 cr in FY26
Syngene CEO Peter Bains resigns, Siddharth Mittal to take over
Syngene shares plunge 23% to 5-year low amid sell-off
Syngene extends Bristol Myers partnership till 2035
The Quarter story
The two most recent quarterly results, compared side-by-side.
Syngene’s revenue and market valuation contracted sharply in Q1 FY27 following a major corporate restructuring, with profitability margins halving but operating costs staying lean.
Other direct costs fall from ₹260 Cr in Q4 FY26 to ₹30 Cr in Q1 FY27, keeping input spending lean.
Reported revenue falls from ₹10,587 Cr in Q4 FY26 to ₹761 Cr in Q1 FY27, reflecting a major scale reduction.
Other expenses drop from ₹1,216 Cr in Q4 FY26 to ₹110 Cr in Q1 FY27, reducing overhead pressure.
EBITDA margin drops from 30.8% in Q4 FY26 to 15.2% in Q1 FY27, compressing core profitability.
Depreciation and finance costs fall from ₹1,115 Cr in Q4 FY26 to ₹112 Cr in Q1 FY27, lowering fixed financial burdens.
PAT margin falls from 14.5% in Q4 FY26 to 0.1% in Q1 FY27, leaving almost no net profit buffer.
Net cash reserves decline from ₹18,003 Cr in Q4 FY26 to ₹1,541 Cr in Q1 FY27, tightening liquidity.
Company insights, generated from the most recent coverage.
Q1 FY27 operating EBITDA margin of just 12.3% is far below management's mid-20s full-year guidance, so the H2 ramp must deliver a sharp margin recovery for the FY27 target to stay credible.
Siddharth Mittal took over as MD & CEO on 1 Jul 2026 (succeeding Peter Bains), with Kiran Mazumdar-Shaw moving to Executive Chairperson from 1 Apr 2026 — fresh leadership now owns the H2 FY27 recovery and CDMO pivot.
Up ~5% intraday to ₹365 on Oct 12, gapping up and holding near day's high — a bounce from the 52-week low zone (~₹344) after a 12% 3-month slide, with no identifiable fresh catalyst.